

Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express HI Highway, Goregaon(E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



29 March 2020.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Update on Halol facility

This is with respect to our communication dated December 13, 2019 regarding the USFDA inspection at the Company's Halol (Gujarat) facility from December 03-13, 2019 and issuance of Form 483 by USFDA with eight observations.

We now wish to inform you that the Company has received a communication from the USFDA indicating that the Halol facility has been classified as "Official Action Indicated" (OAI). The OAI classification implies interalia that the USFDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved. The Company continues to manufacture and distribute existing products for the US market, thereby not likely to have any adverse impact on current business from the facility.

Sun Pharma continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company's remedial action.

Sun Pharma remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

This is for your information and records.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd.
Sd/-

Ashok I. Bhuta
Compliance Officer
Contact No.: +91 22 4324 2231

Note: In view of the lockdown due to COVID-19 pandemic, we are submitting unsigned letter.